Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
You may also be interested in...
New Chief Scientific Officer Jacques Dumas says the clinical-stage firm intends to leverage its expertise in nucleoside discovery to create drug candidates for cancer and other infectious diseases. Concurrent with its drug development in hepatitis C, Idenix plans to address these other indications with the help of partners.
It may take four to five years for next-generation oral hepatitis C therapies to take hold in China, and Johnson & Johnson subsidiary Janssen Inc. isn’t wasting any time stepping up efforts to increase disease awareness via partnerships.
Roche Pharmaceuticals Asia Pacific Head Luke Miels talks to PharmAsia News about the company’s recent deal with Ascletis, its thinking on China’s hepatitis C market and additional opportunities for out-licensing.